Vedolizumab is a humanized immunoglobin G1 monoclonal antibody that binds the gut
homing receptor α4β7 integrin and inhibits its ability to bind mucosal addressin cell
adhesion molecule-1, which is expressed on the endothelium within the gut-associated
lymphoid tissues and mesenteric lymph nodes (MLN) [
[1]
]. Therefore, vedolizumab prevents lymphocytes from extravasating into gastrointestinal
mucosal tissues and regional lymph nodes, thus attenuating intestinal inflammation
[
[1]
]. The efficacy of vedolizumab for inflammatory bowel disease was demonstrated in
patients with ulcerative colitis [
[2]
] and Crohn’s disease (CD) [
[3]
]. We describe a case of primary gastrointestinal diffuse large B cell lymphoma (DLBCL)
in which vedolizumab induced complete metabolic remission.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.J Pharmacol Exp Ther. 2009; 330: 864-875https://doi.org/10.1124/jpet.109.153973
- Vedolizumab as induction and maintenance therapy for ulcerative colitis.N Engl J Med. 2013; 369: 699-710https://doi.org/10.1056/NEJMoa1215734
- Vedolizumab as induction and maintenance therapy for Crohn's disease.N Engl J Med. 2013; 369: 711-721https://doi.org/10.1056/NEJMoa1215739
- Lymphoma dissemination: the other face of lymphocyte homing.Blood. 2007; 110: 3102-3111https://doi.org/10.1182/blood-2007-05-075176
- In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.mAbs. 2013; 5: 842-850https://doi.org/10.4161/mabs.26392
- Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and alpha4beta7.Cancer Res. 1997; 57: 930-936
- Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.Cancer Cell. 2004; 5: 191-199https://doi.org/10.1016/s1535-6108(04)00019-4
- The activated conformation of integrin β 7 is a novel multiple myeloma-specific target for CAR T cell therapy.Nat Med. 2017; 23: 1436-1443https://doi.org/10.1038/nm.4431
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.Lancet. 2009; 374: 1617-1625https://doi.org/10.1016/S0140-6736(09)61302-7
- Preferential expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin’s lymphomas.Am J Pathol. 1997; 150: 919-927
- Diffuse large B-cell lymphoma.N Engl J Med. 2021; 384: 842-858https://doi.org/10.1056/NEJMra2027612
Article info
Publication history
Published online: October 15, 2022
Accepted:
September 19,
2022
Received in revised form:
September 10,
2022
Received:
June 25,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
